Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst

22nd May 2018 Uncategorised 0

Amgen won FDA approval for its highly anticipated migraine drug, Aimovig, last week, and yesterday it racked up its fifth nod for the bone drug Prolia. But investors may be too optimistic that pipeline meds will deliver enough to justify its $118 billion valuation, analysts argue.

More: Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst
Source: fierce